Biocracked
Approach 4, conceptual metaphor, in palette D, bold color field.

A single glass beaker-shaped water carafe sits at center frame on a saturated tangerine-orange seamless backdrop, photographed straight-on at slight low angle. The carafe is filled with clear water, and a small, cleanly drilled hole near its base releases a thin, steady stream that falls into a shallow white ceramic dish below, with a few droplets frozen mid-air. This stands for NAD+ draining away through a leak. A tiny electric green (#00e676) rubber stopper is held by a gloved fingertip entering from the right, about to plug the hole. Lighting is crisp, high-key studio light from upper left, giving sharp specular highlights on the glass and soft, warm-neutral shadows on the backdrop. Mood: clever, precise, optimistic but skeptical. No text or labels.
Longevity

The NAD+ Thief in Your Brain: Blocking CD38 Raised Brain NAD+

Nova Chen · · 4 min read

If you buy NMN or NR to refill your NAD+ tank, a new preclinical study asks an awkward question: what if the tank has a leak? The leak in question is an enzyme called CD38. In rodents, a drug that blocks it raised NAD+ in the brain and eased movement problems in a Parkinson's disease model.

Before anyone clears a shelf of supplements, here is the catch. The compound is CVN14, an experimental drug from Cerevance. It is not a supplement, it is not available to consumers, and the work was done in rats, mice and cell cultures, not people.

What is the 'NAD+ thief'?

NAD+ is a cofactor that cells need for many core processes. It tends to decline with age, and the authors point to two causes: less NAD+ is made, and more is used up.

CD38 sits on the consumption side. It is an NAD+-consuming enzyme (an NADase), and its expression rises with ageing and disease. The researchers argue that this likely contributes to the age-related drop in NAD+. They also note genetic links between CD38 and Parkinson's disease (PD), which gives them a reason to study it in that context.

Using NETSseq datasets from human post-mortem brain tissue, the team found that CD38 is highly enriched in astrocytes, the star-shaped support cells of the brain. Neurons are not the main place this enzyme is found.

The key finding: block CD38, brain NAD+ goes up

CVN14 is a brain-penetrant, selective CD38 inhibitor that the group had described previously. In this paper they characterised it in detail.

  • Potency: It inhibited recombinant CD38 with IC50 values of 19.0 nM (human), 5.1 nM (rat) and 2.4 nM (mouse). Lower numbers mean more potent, so it was strongest against the mouse enzyme and weakest, though still potent, against the human one.
  • Selectivity: It had no activity at CD157, the closest CD38 relative, or at other NADases.
  • Brain NAD+: It increased brain NAD+ in both rats and mice.
  • Knockout control: It had no effect in CD38 knockout mice. This supports the idea that the NAD+ rise comes from blocking CD38 and not from some other NAD-chewing enzyme.

The abstract does not give the size of the NAD+ increase, so no percentage claims are made here.

The Parkinson's angle

The researchers then tested whether this NAD+ boost mattered in models of Parkinson's disease, which is marked by the buildup of misfolded α-synuclein protein.

In cell culture: In rat mesencephalic cultures challenged with α-synuclein, CVN14 showed evidence of increasing the survival of dopaminergic neurons. Those are the cells that die in PD. It also reduced the number of neurons positive for pSer129 α-synuclein, a marker of pathological protein. The authors say this supports further investigation of a possible role for CD38 inhibition in clearing pathological protein. The wording is cautious, and it should be read that way.

In rats: In a rat model using AAV1/2-hA53T α-synuclein, CVN14 improved motor function in the cylinder test. That is one behavioural readout, in one animal model.

Read this before you get excited

The limits are substantial:

  • Not human data. Everything here comes from rats, mice, and cultured cells, plus human post-mortem tissue used only to map where CD38 is expressed.
  • Industry-funded. All authors were employed by Cerevance Ltd, which is developing the compound. That is not a reason to dismiss the work, but it matters for how you weigh it.
  • One behavioural test. The motor benefit was shown in the cylinder test. The conclusions stop at supporting "further investigation."
  • Correlation within the study. The paper shows brain NAD+ rising and neuroprotective signals appearing in the same system. The abstract does not prove that the NAD+ rise alone drives the benefit.
  • No dosing for humans. Nothing here tells you a dose, timing, or safety profile for any person.

What it means for NMN and NR buyers

This paper does not test NMN, NR, or any supplement. It is still useful for thinking about how NAD+ strategies might work in future. Here are the practical takeaways.

1. NAD+ is a supply-and-demand problem. Precursors like NMN and NR address the supply side. CD38 inhibition addresses the demand side. If CD38 is a major drain in an ageing brain, then boosting supply alone may be only half of the equation. That is a hypothesis from this line of research, not a proven fact for supplement users.

2. A combined approach is an idea to watch, not a protocol. The logic of pairing a precursor with a CD38 blocker is appealing. This study did not test it, and there is no human evidence here.

3. Be careful with 'natural CD38 inhibitor' claims. Compounds such as apigenin and quercetin are often described online as CD38 inhibitors. That claim is not from this paper, and their effects on brain NAD+ in people remain unproven. CVN14 was designed to be selective and brain-penetrant. There is no reason to assume a food-derived flavonoid does the same job.

4. Who is this for? Right now, nobody outside a research setting. The stated target is Parkinson's disease and other α-synucleinopathies, and the compound is still preclinical. Anyone with a neurological condition should work with a physician and not try to self-treat based on rodent data.

5. Dose and timing. There are no human dose or timing recommendations to give, because none exist for this compound. Be wary of anyone who claims otherwise.

Bottom line

The study makes a clear case that CD38, concentrated in astrocytes in the human brain, is a credible NAD+ drain worth targeting. A selective inhibitor raised brain NAD+ in rodents, and it did so only when CD38 was present. In Parkinson's models it was linked with better dopaminergic neuron survival in culture, lower pathological α-synuclein signals, and improved motor performance in rats. Whether any of this carries over to humans is the question for future trials.

For now, the main lesson for NAD+ enthusiasts is conceptual: how fast NAD+ is consumed may matter as much as how much precursor you take.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

NC

Written by

Nova Chen

Nova Chen writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

**Approach:** Conceptual metaphor. **Palette:** Bold color field (mustard yellow).

Straight-on, slightly elevated camera view of a pair of identical brass balance scales on a saturated mustard-yellow seamless backdrop. The pans sit perfectly level. One pan holds a small mound of fine white crystalline powder, the other holds an almost identical mound. A third, smaller pan lies tipped and lighter off to the side. Between the scales, a single translucent glass tube coils like a gut, with a tiny electric green (#00e676) glow inside it. This is the only green in the frame. Lighting is soft, directional studio light from the upper left, with crisp, gentle shadows on the yellow surface and warm metallic highlights on the brass. Mood: playful, curious, quietly skeptical. Photorealistic with sharp macro detail on the powder grain and the glass.
supplements

NMN vs NR: First Human Head-to-Head Finds a Tie and a Gut Twist

BY NOVA CHEN ·

For years, NMN has been sold as the premium upgrade to NR. The first human head-to-head trial of NMN, NR and nicotinamide now suggests the two pricey options performed comparably at raising blood NAD+, while nicotinamide did not. The twist: gut microbes appear to convert NR and NMN into nicotinic acid, a potent NAD+ booster in blood experiments. That raises awkward questions about price, niacin and your microbiome. Here's what the 65-person study did and didn't show, including its 14-day, open-label, Nestlé-funded limits.

Approach 1, macro science, in palette D, bold color field.

Extreme close-up microscopy-style image of a single mouse oocyte, a translucent spherical egg, shot straight on at its equator. Inside the cytoplasm, hundreds of mitochondria appear as tiny glowing grains. Most are a muted grey-amber, while a scattered subset of small and large organelles glows vivid electric green (#00e676), clustered unevenly to suggest an uneven response. Fine granular cumulus cells cling to the egg's edge, slightly out of focus. The backdrop is a saturated, flat magenta-violet field, with soft rim light wrapping the egg's glassy membrane and shallow depth of field blurring the edges. The mood is quiet, precise and slightly uneasy, a closer look revealing what the averages hid. Photoreal confocal-meets-studio look, with no text and no labels.
longevity

NMN Rejuvenated Hidden Mitochondria in Aged Eggs, But Not Evenly

BY NOVA CHEN ·

Aged mouse eggs looked mitochondrially normal on average, but a new single-organelle study says the averages were hiding something. Specific subpopulations, high-membrane-potential and small mitochondria, carried elevated mtDNA copy number with age. NMN pulled those back toward young levels, yet pushed large mitochondria the opposite way, and in surrounding cumulus cells it overshot young levels in some groups. No fertility or pregnancy outcomes were measured, the work was in mice, and some authors have patent and company ties. Here is what it means, and does not mean, for women weighing NMN for fertility.

Approach: Macro science (tissue). Palette: B, warm.

Extreme macro photograph in the style of a microscopy image, showing a cluster of rounded, translucent golden fat cells (adipocytes) in the foreground. Fine strands of pale pink-red muscle fibers run diagonally across the frame behind them. Between the two tissues, tiny glistening droplets drift along a thin capillary, suggesting a signal travelling from fat to muscle. Shot at a slight low angle with shallow depth of field, so the foreground cells are crisp and the muscle fibers melt into soft blur. Lit by warm amber backlight that makes the fat cells glow like honey, with copper-toned shadows and a faint rim of light on the fiber edges. One small electric green fluorescent speck sits inside a single droplet as the only cool accent. The mood is quiet, curious and intimate, with a sense of hidden communication inside the body.
longevity

The Fat-Derived Messenger That May Shield Muscle When NAD+ Rises

BY NOVA CHEN ·

Most people who take NMN or NR assume the NAD+ boost works directly inside muscle. A new mouse study in Cell Metabolism suggests fat tissue may be a hidden middleman, releasing a protective protein called Serpina3n into the blood. That signal protected muscle in models of aging, disuse and cancer cachexia, apparently by preserving a key metabolic enzyme. But this is animal research, the authors have filed a patent, and nothing here establishes benefits or doses for human supplement users. Here is what it does and doesn't mean for your routine.

Approach: conceptual metaphor. Palette: D, bold color field.

A single dented red-orange bicycle pump-style hand bellows is not needed; instead, show a translucent glass bell jar standing on a saturated mustard-yellow seamless backdrop, photographed at a slight low three-quarter angle. Inside the jar, a real anatomical-looking sheep heart model in matte deep red sits slightly shrunken-looking under a thin, half-deflated clear balloon, suggesting low oxygen pressure. Beside the jar, a small cracked-open glass ampoule of white powder spills a tiny pale dusting onto the surface, with one thin electric green ribbon tied around the jar's knob. Soft studio key light from the upper left, crisp hard-edged shadow falling to the right, subtle glass reflections. Mood: puzzled, analytical, mixed result, tense but clean.
supplements

NMN Under Low Oxygen in Mice: Didn't Save the Heart, But Did This Instead

BY NOVA CHEN ·

NMN is often pitched as a cellular-protection supplement, but what happens when the stress is repeated low oxygen? A 2026 mouse study in Nutrients found that NMN did not stop hypoxia-induced heart enlargement. It did lower heart stress markers BNP and Myh7, bring spleen measures back toward normal, and shift gut microbiota. It also further raised serum LDH, so the picture is mixed rather than protective. Here is what the paper really shows, what it does not, and why this animal-only, exploratory work should not change anyone's supplement routine yet.

This page is available in